BSE filing, NSE: EMCURE. Summary written from the filing by ALFA Finder's alert engine.
Emcure Pharmaceuticals Ltd: key numbers
- Share price
- ₹1,868.00
- Market cap
- ₹35,438 Cr
- Revenue (annual)
- ₹9,204 Cr
- Net profit (annual)
- ₹924.4 Cr
- P/E (TTM)
- 35.0×Sector 46.5×
- Promoter holding
- 77.82%-0.01% QoQ
- FII holding
- 4.94%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Emcure Pharmaceuticals Ltd
All →Emcure Pharmaceuticals Other Announcement
Emcure Pharmaceuticals submitted its quarterly shareholding pattern for the period ended September 30, 2026. This filing is a routine regulatory compliance disclosure under SEBI.
Emcure Pharmaceuticals Board Meeting Date
Emcure Pharmaceuticals will hold a board meeting on November 03, 2026, to consider and approve the company's standalone and consolidated financial results for the quarter.
Emcure Pharmaceuticals Legal & Regulatory
Emcure Pharmaceuticals received Income-tax Department orders imposing aggregate penalties of Rs. 57.74 Crore for assessment years 2015-16 to 2021-22. The company is evaluating legal remedies.
- Value
- ₹57.74 Cr
Emcure Pharmaceuticals Investor Presentation: Key Takeaways
Emcure reported strong Q1 FY27 momentum with revenue of INR 92,035 Mn and PAT of INR 9,413 Mn for FY26. Strategy focuses on chronic-led domestic expansion and differentiated international portfolios.
Emcure Pharmaceuticals Annual General Meeting
Emcure Pharmaceuticals held its 45th Annual General Meeting on September 21, 2026. The meeting transacted ordinary and special business, including the approval of a final dividend.
Emcure Pharmaceuticals Employee Stock Options
Emcure Pharmaceuticals allotted 11,400 equity shares to employees following the exercise of vested options under the ESOP scheme. This increases the company's total issued share capital.
Other acquisition announcements
All →Emkay Global Financial Services Acquisition Worth ₹21.38 Cr
Emkay Capital, a subsidiary, will acquire Emkay Investment Managers for Rs.21.38 Crore cash. The related-party deal is at arm's length and payable in tranches.
- Value
- ₹21.38 Cr
- Execution
- 90 days
TVS Motor Company Acquisition Worth ₹25,000 Cr
TVS Motor will acquire 100% of Harita ARC Limited, a related-party shell, for a stated Rs 25,000 Crore. It supports the proposed consumer finance demerger.
- Value
- ₹25,000 Cr
Rite Zone Chemcon India Acquisition Worth ₹4.97 Cr
Rite Zone Chemcon's board approved acquiring 51% of Cleanux Green Solution via share swap for about INR 4.97 Crore. The board also approved preferential issues and an EGM on 23 November 2026.
- Value
- ₹4.97 Cr
eClerx Services Acquisition Worth ₹15.57 Cr
eClerx's board approved buying about 2% of Personiv Eclipse Inc. from its wholly owned subsidiary eClerx LLC for USD 1.64 million. The intra-group transfer adds no change to aggregate ownership.
- Value
- ₹15.57 Cr
- Execution
- 1 Month
Fortis Healthcare Acquisition Worth ₹277 Cr
Fortis Healthcare's wholly-owned subsidiary IHL acquired Suguna Hospital's business and land in Bengaluru via slump sale. The cumulative consideration is approximately INR 277 Crore, consummated today.
- Value
- ₹277.0 Cr
Authum Investment & Infrastructure Acquisition
NCLT approved the consortium resolution plan for A A Estates Private Limited, with Authum as a resolution applicant. No consideration amount is disclosed.